Astellas inks neurodegenerative collaboration deal

Share this article:

Astellas continues to expand its list of 2013 partnerships. The drug maker and co-developer Mitokyne announced Monday an R&D agreement to pursue novel drugs that improve mitochondrial functions, with the overall goal being to create drug candidates that could treat genetic, metabolic or neurodegenerative disorders, and even conditions associated with aging. Mitokyne will handle R&D, while Astellas will pick up the clinical development and commercialization side of things.

Monday's announcement is one of a series of recent collaborations, which includes the June R&D agreement with Cytokinetics to target muscle-weakening diseases, May's announcement that it was teaming up with Amgen for cardiovascular and bone diseases, and April's announcement that Astellas and GSK were working on an anemia treatment that dupes the body into thinking it is at a higher altitude to stimulate red blood cell development.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.